Literature DB >> 30311573

p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.

Christie Rodriguez-Ramirez1, Jacques E Nör2.   

Abstract

Head and neck cancers are deadly diseases that are diagnosed annually in approximately half a million individuals worldwide. Growing evidence supporting a role for cancer stem cells (CSCs) in the pathobiology of head and neck cancers has led to increasing interest in identifying therapeutics to target these cells. Apart from the canonical tumor-suppressor functions of p53, emerging research supports a significant role for this protein in physiological stem cell and CSC maintenance and reprogramming. Therefore, p53 has become a promising target to sensitize head and neck CSCs to chemotherapy. In this review, we highlight the role of p53 in stem cell maintenance and discuss potential implications of targeting p53 to treat patients with head and neck cancers.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30311573      PMCID: PMC6396309          DOI: 10.1615/CritRevOncog.2018027353

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  152 in total

1.  p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.

Authors:  Zhen Zhao; Johannes Zuber; Ernesto Diaz-Flores; Laura Lintault; Scott C Kogan; Kevin Shannon; Scott W Lowe
Journal:  Genes Dev       Date:  2010-07-01       Impact factor: 11.361

2.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

3.  A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells.

Authors:  Kyoung-Hwa Lee; Mangmang Li; Aleksandra M Michalowski; Xinyue Zhang; Hongling Liao; Lingyi Chen; Yang Xu; Xiaolin Wu; Jing Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

4.  Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

Authors:  Krupa J Patel; Olivier Trédan; Ian F Tannock
Journal:  Cancer Chemother Pharmacol       Date:  2013-05-17       Impact factor: 3.333

5.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

Review 6.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.

Authors:  Yujun Zhao; Angelo Aguilar; Denzil Bernard; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-11-14       Impact factor: 7.446

7.  Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance.

Authors:  Gina Lee; Robert R Hall; Atique U Ahmed
Journal:  J Stem Cell Res Ther       Date:  2016-10-26

8.  Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.

Authors:  Marianna Szemes; Alexander Greenhough; Zsombor Melegh; Sally Malik; Aysen Yuksel; Daniel Catchpoole; Kelli Gallacher; Madhu Kollareddy; Ji Hyun Park; Karim Malik
Journal:  Neoplasia       Date:  2018-03-03       Impact factor: 5.715

Review 9.  Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved.

Authors:  Li Lu; Menglin Wu; Longhao Sun; Weidong Li; Weihua Fu; Xuening Zhang; Tong Liu
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

10.  Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells.

Authors:  Jie Chen; Jian-Liang Li; Zirong Chen; James D Griffin; Lizi Wu
Journal:  BMC Cancer       Date:  2015-10-26       Impact factor: 4.430

View more
  3 in total

Review 1.  Systemic therapies for salivary gland adenoid cystic carcinoma.

Authors:  Sosuke Sahara; Alexandra E Herzog; Jacques E Nör
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

2.  Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers.

Authors:  Yi Li; Wei Guo; Xiuqin Li; Jianguo Zhang; Moyi Sun; Zhangui Tang; Wei Ran; Kai Yang; Guilin Huang; Longjiang Li
Journal:  Int J Oral Sci       Date:  2021-11-16       Impact factor: 6.344

3.  EGLN1 induces tumorigenesis and radioresistance in nasopharyngeal carcinoma by promoting ubiquitination of p53 in a hydroxylase-dependent manner.

Authors:  Lu Sun; Cheng Wu; Jun Ming; Ergang Guo; Wei Zhang; Lingling Li; Guoqing Hu
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.478

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.